NASDAQ:OCUL

Ocular Therapeutix Stock Forecast, Price & News

$13.62
-0.55 (-3.88 %)
(As of 06/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$13.50
$14.17
50-Day Range
$13.62
$19.16
52-Week Range
$7.14
$24.30
Volume624,662 shs
Average Volume1.04 million shs
Market Capitalization$1.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.15
30 days | 90 days | 365 days | Advanced Chart
Receive OCUL News and Ratings via Email

Sign-up to receive the latest news and ratings for Ocular Therapeutix and its competitors with MarketBeat's FREE daily newsletter.


Ocular Therapeutix logo

About Ocular Therapeutix

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company is involved in the development of OTX-AFS, an aflibercept suprachoroidal injection for the treatment of retinal diseases. It has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.59 out of 5 stars

Medical Sector

457th out of 2,100 stocks

Pharmaceutical Preparations Industry

225th out of 832 stocks

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Ocular Therapeutix (NASDAQ:OCUL) Frequently Asked Questions

Is Ocular Therapeutix a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ocular Therapeutix in the last year. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ocular Therapeutix stock.
View analyst ratings for Ocular Therapeutix
or view top-rated stocks.

What stocks does MarketBeat like better than Ocular Therapeutix?

Wall Street analysts have given Ocular Therapeutix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Ocular Therapeutix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Ocular Therapeutix?

Ocular Therapeutix saw a increase in short interest during the month of May. As of May 28th, there was short interest totaling 7,070,000 shares, an increase of 18.8% from the May 13th total of 5,950,000 shares. Based on an average daily trading volume, of 1,100,000 shares, the short-interest ratio is presently 6.4 days. Currently, 9.3% of the company's shares are sold short.
View Ocular Therapeutix's Short Interest
.

When is Ocular Therapeutix's next earnings date?

Ocular Therapeutix is scheduled to release its next quarterly earnings announcement on Friday, August 6th 2021.
View our earnings forecast for Ocular Therapeutix
.

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix, Inc. (NASDAQ:OCUL) released its quarterly earnings results on Wednesday, May, 5th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.04. The biopharmaceutical company had revenue of $7.34 million for the quarter, compared to the consensus estimate of $8.12 million. Ocular Therapeutix had a negative net margin of 591.81% and a negative trailing twelve-month return on equity of 103.20%.
View Ocular Therapeutix's earnings history
.

How has Ocular Therapeutix's stock price been impacted by Coronavirus (COVID-19)?

Ocular Therapeutix's stock was trading at $5.35 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OCUL stock has increased by 154.6% and is now trading at $13.62.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for OCUL?

4 analysts have issued 1-year price targets for Ocular Therapeutix's shares. Their forecasts range from $14.00 to $30.00. On average, they anticipate Ocular Therapeutix's share price to reach $24.80 in the next year. This suggests a possible upside of 82.1% from the stock's current price.
View analysts' price targets for Ocular Therapeutix
or view top-rated stocks among Wall Street analysts.

Who are Ocular Therapeutix's key executives?

Ocular Therapeutix's management team includes the following people:
  • Mr. Antony Mattessich, Pres, CEO & Director (Age 54, Pay $907.55k)
  • Dr. Michael H. Goldstein M.M., M.D., M.B.A., Pres of Ophthalmology & Chief Medical Officer (Age 54, Pay $550.76k)
  • Mr. Donald Notman Jr., Chief Financial Officer
  • Dr. Peter K. Jarrett Ph.D., Chief Scientific Officer (Age 64)
  • Mr. Philip C. Strassburger, Gen. Counsel (Age 61)
  • Mr. William H. Ransone II, VP of Global Sales & Marketing
  • Mr. Christopher G. White, Sr. VP of Bus. & Corp. Devel. (Age 59)
  • Ms. Tracy Smith, VP of HR
  • Mr. Scott Corning, Sr. VP of Commercial
  • Dr. Rabia Gurses Ozden, Sr. VP of Clinical Devel. (Age 52)

Who are some of Ocular Therapeutix's key competitors?

What other stocks do shareholders of Ocular Therapeutix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocular Therapeutix investors own include Clearside Biomedical (CLSD), Northwest Biotherapeutics (NWBO), Novavax (NVAX), (CELG), Dynavax Technologies (DVAX), Omeros (OMER), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and SCYNEXIS (SCYX).

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

Who are Ocular Therapeutix's major shareholders?

Ocular Therapeutix's stock is owned by many different institutional and retail investors. Top institutional investors include Opaleye Management Inc. (8.49%), BlackRock Inc. (7.71%), Deltec Asset Management LLC (2.76%), Victory Capital Management Inc. (2.04%), Emerald Mutual Fund Advisers Trust (1.78%) and Emerald Advisers LLC (1.70%). Company insiders that own Ocular Therapeutix stock include Opaleye Management Inc, Richard L Md Lindstrom and Summer Road Llc.
View institutional ownership trends for Ocular Therapeutix
.

Which major investors are selling Ocular Therapeutix stock?

OCUL stock was sold by a variety of institutional investors in the last quarter, including D. E. Shaw & Co. Inc., Nuveen Asset Management LLC, Renaissance Technologies LLC, Lisanti Capital Growth LLC, Deltec Asset Management LLC, UBS Group AG, Bank of New York Mellon Corp, and JPMorgan Chase & Co..
View insider buying and selling activity for Ocular Therapeutix
or view top insider-selling stocks.

Which major investors are buying Ocular Therapeutix stock?

OCUL stock was acquired by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Rubric Capital Management LP, Kamunting Street Capital Management L.P., BlackRock Inc., Emerald Mutual Fund Advisers Trust, Millennium Management LLC, Castleark Management LLC, and Great Point Partners LLC. Company insiders that have bought Ocular Therapeutix stock in the last two years include Opaleye Management Inc, and Summer Road Llc.
View insider buying and selling activity for Ocular Therapeutix
or or view top insider-buying stocks.

How do I buy shares of Ocular Therapeutix?

Shares of OCUL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ocular Therapeutix's stock price today?

One share of OCUL stock can currently be purchased for approximately $13.62.

How much money does Ocular Therapeutix make?

Ocular Therapeutix has a market capitalization of $1.04 billion and generates $17.40 million in revenue each year. The biopharmaceutical company earns $-155,640,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis.

How many employees does Ocular Therapeutix have?

Ocular Therapeutix employs 181 workers across the globe.

What is Ocular Therapeutix's official website?

The official website for Ocular Therapeutix is www.ocutx.com.

Where are Ocular Therapeutix's headquarters?

Ocular Therapeutix is headquartered at 15 CROSBY DRIVE, BEDFORD MA, 01730.

How can I contact Ocular Therapeutix?

Ocular Therapeutix's mailing address is 15 CROSBY DRIVE, BEDFORD MA, 01730. The biopharmaceutical company can be reached via phone at (781) 357-4000 or via email at [email protected]


This page was last updated on 6/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.